Cargando…
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populat...
Autores principales: | Szemiel, Agnieszka M., Merits, Andres, Orton, Richard J., MacLean, Oscar A., Pinto, Rute Maria, Wickenhagen, Arthur, Lieber, Gauthier, Turnbull, Matthew L., Wang, Sainan, Furnon, Wilhelm, Suarez, Nicolas M., Mair, Daniel, da Silva Filipe, Ana, Willett, Brian J., Wilson, Sam J., Patel, Arvind H., Thomson, Emma C., Palmarini, Massimo, Kohl, Alain, Stewart, Meredith E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496873/ https://www.ncbi.nlm.nih.gov/pubmed/34534263 http://dx.doi.org/10.1371/journal.ppat.1009929 |
Ejemplares similares
-
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
por: Willett, Brian J., et al.
Publicado: (2022) -
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
por: Willett, Brian J., et al.
Publicado: (2022) -
The Timing and Magnitude of the Type I Interferon Response Are Correlated with Disease Tolerance in Arbovirus Infection
por: Hardy, Alexandra, et al.
Publicado: (2023) -
A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research
por: Rihn, Suzannah J., et al.
Publicado: (2021) -
The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance
por: Lista, Maria Jose, et al.
Publicado: (2022)